Table 1 Characteristics of the included studies and outcome events
Study | Countries | Centers | Publication | Type of migraine | Treatment group, (No. of participants) | Total number | Age range | Female (%) | Mean age ± SD (year) | Study period | Outcome Events |
|---|---|---|---|---|---|---|---|---|---|---|---|
Goadsby et al 2020 (NCT02848326) | USA | 78 | Lancet Neurol | episodic | Atogepant 10 mg QD (93) vs.30 mg QD (183) vs.60 mg QD (186) vs.30 mg BID (86) vs.60 mg BID (91) vs. PLA (186) | 825 | 18y-75y | 10 mg QD: 88 30 mg QD: 91 60 mg QD: 84 30 mg BID: 85 60 mg BID: 91 PLA: 83 | 10 mg QD:39.4 ± 12.4 30 mg QD:41.0 ± 13.6 60 mg QD:40.4 ± 11.7 30 mg BID:38.5 ± 11.2 60 mg BID:39.7 ± 11.9 PLA:40.5 ± 11.7 | 12w | a b c d e |
Ailani et al 2021 (NCT03777059) | USA | 138 | NEJM | episodic | Atogepant 10 mg QD (221) vs.30 mg QD (228) vs.60 mg QD (231) vs. PLA (222) | 902 | 18y-80y | 10 mg QD: 90.5 30 mg QD: 89.5 60 mg QD: 86.1 PLA: 89.2 | 10 mg QD:41.1 ± 12.0 30 mg QD:42.1 ± 11.7 60 mg QD:42.5 ± 12.4 PLA: 40.3 ± 12.8 | 12w | a b c d e f g h |
Allergan et al 2021 (NCT03700320) | USA | 112 | / | episodic | Atogepant 60 mg QD | 739 | 18y-80y | 60 mg QD: 88.2 PLA: 87.8 | 60 mg QD: 41.1 ± 12.1 PLA: 42.5 ± 12.03 | 52w | a |